AAM Response to CA Governor Newsom Signing AB 824
WASHINGTON, DC (October 8, 2019)--
"As the Federal Trade Commission has found, recent patent litigation settlements have overwhelmingly accelerated the launch of more affordable generic and biosimilar medicines prior to the branded drug's patent expiration date.